Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK3280 in Idiopathic Pulmonary Fibrosis
NCT05424887Phase 2Unknown
- Sponsor
- Ark Biosciences
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AK3280 in idiopathic pulmonary fibrosis (IPF), sponsored by Ark Biosciences. Status: unknown.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05424887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424887.